Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 20.97% is in line with its 5-year average of 19.47%, near the high end of its 5-year range (15.25%–23.37%).
0.00% above its 12-month average of 20.97%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.76%.
OPERATING MARGIN
20.97%
OPERATING MARGIN AVG TTM
20.97%
OPERATING MARGIN AVG 3Y
20.72%
OPERATING MARGIN AVG 5Y
19.47%
OPERATING MARGIN AVG 10Y
17.34%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.00%
CURRENT VS 3Y AVG
+1.20%
CURRENT VS 5Y AVG
+7.69%
CURRENT VS 10Y AVG
+20.91%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
14.90%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+40.74%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$17.21B
Operating Margin
20.97%
TTM Avg
20.97%
3Y Avg
20.72%
5Y Avg
19.47%
Market Cap
$16.26B
Operating Margin
12.32%
TTM Avg
13.70%
3Y Avg
16.38%
5Y Avg
21.25%
Market Cap
$18.72B
Operating Margin
15.73%
TTM Avg
16.64%
3Y Avg
15.15%
5Y Avg
12.43%
Market Cap
$15.38B
Operating Margin
24.99%
TTM Avg
19.38%
3Y Avg
20.05%
5Y Avg
20.47%
Market Cap
$19.82B
Operating Margin
-18.62%
TTM Avg
-9.28%
3Y Avg
-0.91%
5Y Avg
-0.93%
Market Cap
$14.27B
Operating Margin
39.88%
TTM Avg
32.73%
3Y Avg
24.94%
5Y Avg
21.46%
Market Cap
$21.16B
Operating Margin
44.49%
TTM Avg
47.77%
3Y Avg
49.26%
5Y Avg
45.01%
Market Cap
$13.17B
Operating Margin
12.35%
TTM Avg
9.13%
3Y Avg
12.39%
5Y Avg
13.51%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $17.21B | 20.97% | 20.97% | 20.72% | 19.47% |
| Revvity, Inc. (RVTY)vs › | $16.26B | 12.32% | 13.70% | 16.38% | 21.25% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.72B | 15.73% | 16.64% | 15.15% | 12.43% |
| Solventum Corporation (SOLV)vs › | $15.38B | 24.99% | 19.38% | 20.05% | 20.47% |
| Viatris Inc. (VTRS)vs › | $19.82B | -18.62% | -9.28% | -0.91% | -0.93% |
| Exelixis, Inc. (EXEL)vs › | $14.27B | 39.88% | 32.73% | 24.94% | 21.46% |
| STERIS plc (STE)vs › | $20.46B | 18.91% | 17.21% | 17.04% | 16.18% |
| United Therapeutics Corporation (UTHR)vs › | $21.16B | 44.49% | 47.77% | 49.26% | 45.01% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.17B | 12.35% | 9.13% | 12.39% | 13.51% |
| Penumbra, Inc. (PEN)vs › | $12.54B | 12.45% | 10.35% | 7.09% | 3.40% |
Gross Margin
28.8%
Operating Margin
21.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 20.76% |
| 2026-03-31 | 20.03% |
| 2025-12-31 | 21.63% |
| 2025-09-30 | 21.49% |
| 2025-06-30 | 20.94% |
| 2025-03-31 | 20.32% |
| 2024-12-31 | 23.37% |
| 2024-09-30 | 21.05% |
| 2024-06-30 | 19.91% |
| 2024-03-31 | 20.36% |
| 2023-12-31 | 17.52% |
| 2023-09-30 | 17.24% |
| 2023-06-30 | 17.01% |
| 2023-03-31 | 19.86% |
| 2022-12-31 | 19.39% |
| 2022-09-30 | 20.28% |
| 2022-06-30 | 17.15% |
| 2022-03-31 | 19.40% |
| 2021-12-31 | 17.78% |
| 2021-09-30 | 18.17% |
| 2021-06-30 | 15.25% |
| 2021-03-31 | 18.31% |
| 2020-12-31 | 21.18% |
| 2020-09-30 | 20.15% |
| 2020-06-30 | 14.70% |
| 2020-03-31 | 15.38% |
| 2019-12-31 | 15.71% |
| 2019-09-30 | 13.87% |
| 2019-06-30 | 16.47% |
| 2019-03-31 | 12.90% |
| 2018-12-31 | 15.96% |
| 2018-09-30 | 15.02% |
| 2018-06-30 | 13.72% |
| 2018-03-31 | 12.34% |
| 2017-12-31 | 13.70% |
| 2017-09-30 | 15.54% |
| 2017-06-30 | 15.33% |
| 2017-03-31 | 14.96% |
| 2016-12-31 | 11.91% |
| 2016-09-30 | 11.70% |
| 2016-06-30 | 13.32% |
| 2016-03-31 | 12.92% |
| 2015-12-31 | -0.93% |
| 2015-09-30 | 7.81% |
| 2015-06-30 | 8.95% |
| 2015-03-31 | 7.69% |
| 2014-03-31 | 2.36% |
